Mirtazapine augmentation enhances cognitive and negative symptoms in schizophrenic patients treated with risperidone: a randomised controlled trial
ISRCTN | ISRCTN54975957 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN54975957 |
Secondary identifying numbers | N/A |
- Submission date
- 27/05/2009
- Registration date
- 01/12/2009
- Last edited
- 01/12/2009
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Sang Hyuk Lee
Scientific
Scientific
Department of Psychiatry
Bundang CHA Hospital
CHA University School of Medicine
351 Yatap-Dong
Bundang-Gu
Seongnam-Si
463-712
Korea, South
Study information
Study design | Double-blind randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | The effect of mirtazapine augmentation of risperidone in the treatment of cognitive and negative symptoms of schizophrenia: a randomised controlled trial |
Study objectives | Our hypothesis is that mirtazapine augmentation to the 'typical' atypical antipsychotics, risperidone that demonstrates potent inhibitors of of 5-hydroxytryptamine2 (5-HT2), alpha-2 adrenergic receptors can enhance cognitive function and reduce negative symptoms in patients with schizophrenia. |
Ethics approval(s) | Bundang CHA Institutional Review Board (Ethics Committee) approved on the 22nd December 2008 (ref: 2008-15) |
Health condition(s) or problem(s) studied | Schizophrenia |
Intervention | Mirtazapine was added to the on-going pharmacotherapy with risperidone in the mirtazapine group. The initial dosage was 15 mg/day at bedtime for the first two weeks. Thereafter, a daily dose of 30 mg/day was given at bedtime through the remainder of the study (six weeks). Doses of risperidone were fixed for the duration of the study. |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Phase IV |
Drug / device / biological / vaccine name(s) | Mirtazapine, risperidone |
Primary outcome measure | 1. Positive and Negative Syndrome Scale (PANSS), collected for each patient at week 0, week 2, week 4, and week 8 2. Scale for the Assessment of Negative Symptoms (SANS), collected for each patient at week 0, week 2, week 4, and week 8 3. Digit Span of K-WAIS (Korean-Wechsler Adult Intelligence Scale), collected at weeks 0 and 8 4. Controlled Oral Word Association Test (COWAT), collected at weeks 0 and 8 5. Korean-Complex Figure Test (K-CFT), collected at weeks 0 and 8 6. Korean-Auditory Verbal Learning Test (K-AVLT), collected at weeks 0 and 8 7. Estimated intelligence quotient (IQ) by the sum of Vocabulary scores and Block Design scores on the K-WAIS, collected at weeks 0 and 8 8. Timed Coding Test, collected at weeks 0 and 8 |
Secondary outcome measures | 1. Barnes Akathisia Rating Scale, collected at weeks 0 and 8 2. Simpson-Angus Scale for Expyramidal Side-effects, collected at weeks 0 and 8 3. Clinical Global Impression (CGI), collected at weeks 0 and 8 4. Hamilton Rating Scale for Depression (HAMD), collected at weeks 0 and 8 5. Body weight, collected at weeks 0 and 8 6. Abdominal circumference, collected at weeks 0 and 8 |
Overall study start date | 01/10/2008 |
Completion date | 31/03/2009 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Both |
Target number of participants | 25 |
Key inclusion criteria | 1. Aged between 21 and 70 years, either sex 2. Diagnosed with schizophrenia based on the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (SCID) 3. Receiving treatment of oral risperidone (Risperdal Quicklet®) or RLAI (risperidone long acting-injection) as outpatients. In addition, the subjects had to have been stable for at least eight weeks in an outpatient setting immediately prior to initiation of this study. 4. Presence of positive or negative symptoms or both, resulting in the illness of at least moderate severity (greater than or equal to 4 on the Clinical Global Impression [CGI] Severity Scale) |
Key exclusion criteria | 1. Evidence of organic mental disorder or mental retardation 2. Severe drug or alcohol dependence that required inpatient treatment and/or detoxification 3. Presence of a depressive episode. To exclude subjects with depressive episodes, the Hamilton Rating Scale for Depression (HAMD) was used (patients who scored more than 17 on HAMD were excluded). 4. Other conditions, such as a serious medical condition, a history of bipolar or schizoaffective disorder, substance misuse, suicidality, possibility of pregnancy, lactation, or inability/unwillingness to use contraception |
Date of first enrolment | 01/10/2008 |
Date of final enrolment | 31/03/2009 |
Locations
Countries of recruitment
- Korea, South
Study participating centre
Department of Psychiatry
Seongnam-Si
463-712
Korea, South
463-712
Korea, South
Sponsor information
Bundang CHA Hospital (South Korea)
Hospital/treatment centre
Hospital/treatment centre
c/o Sang-Hyuk Lee, M.D.,Ph.D.
Assistant Professor, Department of Psychiatry
CHA University School of Medicine
351 Yatap-Dong
Bundang-Gu
Seongnam-Si
463-712
Korea, South
https://ror.org/04yka3j04 |
Funders
Funder type
Hospital/treatment centre
Bundang CHA Hospital (South Korea)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |